Microbiota and Diabetes Mellitus
15 Years of experience with DPP 4 Inhibition – Current clinical
Antidiabetic medications and cardiovascular protection
Empagliflozin a novel approach to type 2 DM
The ideal Rapid Partner
Diabetes Clinic in Remote Area
The shortcut to early and tight glycemic control
When not to Escalate
Diabetic Dyslipidemia, a closer look
Contra Haytham Badr screening of Cardiovascular Disease in type 2 Diabetes
Role of SMBG in Type 2 diabetes
Tubulocentric View of diabetic kidney disease
Diabetes and Hypertension
Heterogeneity and Phenotypic variability in Diabetes
Diabetes & Brain
Insulin initiation barriers and advances in basal insulin therapy